TrialJCO precision oncology2022

Safety, Feasibility, and Merits of Longitudinal Molecular Testing of Multiple Metastatic Sites to Inform mTNBC Patient Treatment in the Intensive Trial of Omics in Cancer.

Kimberly A Burton et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.